Study Finds Big Shift in Who's Using GLP-1 Meds Like Ozempic
WEBJul 23, 2024 — About 1 million people became new GLP-1 users during that period in time, results show. Researchers classified them based on whether they had diabetes, obesity or some other related medical condition. GLP-1 drugs work by adjusting a person’s hormone levels and suppressing appetite.
Study shows shift in GLP-1 drug use for obesity, not diabetes
WEBJul 23, 2024 — The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs' original purpose, which was to treat Type 2 diabetes, a new study finds.
Study Finds Big Shift in Who's Using GLP-1 Meds Like Ozempic
WEBJul 23, 2024 — Semaglutide -- the drug sold as Ozempic and Wegovy -- is being prescribed disproportionately to females, whites, and those with a BMI of 30 or more, indicating obesity, results show.
Research shows GLP-1 drugs are effective but complex
WEBMay 30, 2024 — While experts caution against overusing GLP-1RAs or viewing them as a universal cure-all for obesity, physicians and researchers agree that the drugs are highly effective for weight management and Type 2 diabetes treatment.
Study Finds Big Shift in Who's Using GLP-1 Meds Like Ozempic
WEBJul 23, 2024 — GLP-1 drugs work by adjusting a person’s hormone levels and suppressing appetite. Semaglutide -- the drug sold as Ozempic and Wegovy -- is being prescribed disproportionately to females, whites, and those with a BMI of 30 or more, indicating obesity, results show. The findings were published July 22 in the Annals of Internal …
Study Shows 85% Of Patients Stop GLP-1s For Obesity After 2 Years - Forbes
WEBJul 11, 2024 — A recent survey conducted in late May of this year shows that just 34% of United States employer health plans offer coverage of GLP-1 drugs for both diabetes management and weight loss.
Study indicates surge in GLP-1RA prescriptions to treat obesity …
WEBJul 22, 2024 — Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists...
New Cedars-Sinai Study Investigates Shifting Trends in GLP-1RA …
WEBInvestigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs)—prescription medications sold under popular drug names like Ozempic and Wegovy—in the United States.
Research shows GLP-1 receptor agonist drugs are effective but …
WEBJun 4, 2024 — Study shows new drug suppresses systemic inflammatory response syndrome resulting from bypass surgery
GLP-1 agonists: US sees 700% increase over four years in ... - The BMJ
WEBJul 23, 2024 — The paper, published in Annals of Internal Medicine, showed a decreasing trend in the proportion of new GLP-1RA users with type 2 diabetes from 87.59% in 2019 to 70.9% in 2023. While the proportion declined, however, the number of patients more than doubled, from 205 109 to 459 278.